Affinity Asset Advisors has disclosed a new position in Praxis Precision Medicines, acquiring 185,000 shares valued at $54.53 million during the fourth quarter. The stake represents 3.11% of the fund's reportable assets. Praxis shares were trading at $317.25 as of 13 February 2026, up 266% over the past year. The Boston-based clinical-stage biotechnology company develops therapies for central nervous system disorders, with lead candidates targeting major depressive disorder, essential tremor and epilepsy. The company expects two new drug application submissions by mid-February and holds approximately $956 million in cash and investments, sufficient to fund operations into 2028. Third-quarter research and development expense reached $65.8 million, whilst net loss widened to $73.9 million.

Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio CAMBRIDGE, Mass.--Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system

CAMBRIDGE, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced